assignment
Not Recruiting

Phase III Randomized, Double-Blind Study of Everolimus Plus Adjuvant Hormone Therapy in ER+ HER2- High-Risk Breast Cancer Patients

Trial ID
2024-516198-61-00
Protocol
UC-0140/1208
Sponsor
Unicancer

Register record, history and transparency: CTIS.eu

Trial statistics

science
2
test molecules
location_city
49
research sites
public
3
countries
medical_information
1
disease
person_search
52
investigators

Diseases & Conditions

Hormone receptor positive HER2 negative breast cancer

Objectives

The primary objective of this study is to evaluate the benefit of adding **everolimus** to standard endocrine treatments on disease-free survival (DFS) in women with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free. This is clinically relevant as improving DFS can potentially reduce the risk of cancer recurrence, thereby enhancing long-term patient outcomes.

Secondary objectives include:

  • Assessing the impact of everolimus on overall survival (OS), event-free survival (EFS), distant metastasis-free survival (DMFS), and bone metastatic-free survival (BMFS).
  • Evaluating the effect of everolimus on DFS and OS in ER+, PR+ and ER+/PR- subgroups.
  • Determining the impact of everolimus on the incidence of secondary cancers.
  • Assessing the safety profile of everolimus in combination with hormone therapy.
  • Investigating the predictive value of mTOR activation markers on DFS through IHC analysis of primary tumors for pS6K and p4EBP.
  • Conducting other translational analyses linking cancer biology with outcomes.
  • Conducting quality of life sub-studies.
  • Evaluating EFS and DMFS in low-risk patients according to the EPClin score.
  • Conducting a sociologic study.

Participants

The clinical trial involves a total of **198 participants** who are exclusively **female** and aged **18 years or older**. The study population consists of patients with a high risk of relapse, specifically those with **ER+ and HER2- primary non-metastatic breast cancer** who remain disease-free. Participants were selected based on specific health criteria, including adequate hematological, hepatic, and renal function, as well as a WHO Performance status of 0 or 1. The trial excludes individuals with clinically or radiologically detectable metastases at the time of inclusion. Participants are required to have histologically proven invasive unilateral or bilateral breast cancer, with the primary tumor completely resected. The trial population is characterized by their engagement in adjuvant hormone therapy, either initiated or ongoing for up to four years, with treatments such as tamoxifen, letrozole, anastrozole, or exemestane. The study does not include male subjects, and the population is considered vulnerable, necessitating signed written informed consent from all participants.

Plans and Procedures

The clinical trial is a **randomized**, **double-blind**, controlled, multicenter Phase III study designed to evaluate the safety and efficacy of adding **everolimus** to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free. The primary objective is to assess the benefit on disease-free survival (DFS) by incorporating everolimus for a duration of two years alongside standard endocrine treatments. The trial is expected to conclude by March 31, 2025, with recruitment having commenced on June 5, 2013.

Participants will be randomly assigned to receive either everolimus or a placebo, both administered orally in tablet form. The maximum treatment period for both groups is 24 months. The study includes several key visits: an initial screening visit to confirm eligibility based on criteria such as age, hematological, hepatic, and renal function, and the absence of detectable metastases. Follow-up visits will be scheduled periodically to monitor the participants' health status, adherence to the treatment regimen, and any adverse events. The end-of-study visit will occur at the conclusion of the treatment period or upon early termination.

Participant involvement is expected to last up to 24 months, depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any new medical conditions that contraindicate continued participation. The primary endpoint is the disease-free survival rate post-randomization, with secondary endpoints including overall survival, efficacy in specific subgroups, and quality of life assessments. The trial also aims to explore the predictive value of mTOR activation markers on DFS and other translational analyses linking cancer biology with outcomes.

Treatment

The clinical trial involves the administration of **Afinitor** 5 mg tablets, which contain the active substance **everolimus**. Everolimus is a chemical compound classified under the ATC code L01EG02. The pharmaceutical form of the medication is a tablet, and it is administered orally. Participants in the trial will receive a maximum daily dose of 10 mg, with a total maximum dose of 1825 mg over a treatment period of 24 months. The medication is manufactured by Novartis Europharm Limited and is not a paediatric formulation. The trial aims to evaluate the benefit of adding everolimus to standard endocrine treatments in women with high risk of relapse, ER+ and HER2- primary breast cancer.

In addition to the experimental treatment, a **placebo** is used as a comparator in the study. The placebo is also in tablet form and is administered orally. It contains no active pharmaceutical ingredients and serves as a control to assess the efficacy and safety of the experimental treatment. The placebo is administered over the same treatment period of 24 months, with no active dose, ensuring that any observed effects can be attributed to the active treatment. Compliance with the dosing schedule will be monitored throughout the trial to ensure adherence to the protocol.

Efficacy

The efficacy of the clinical trial will be assessed primarily through the evaluation of **disease-free survival (DFS)** rates after randomization. DFS is defined as the time until local, regional, or metastatic relapse, the occurrence of a new contralateral breast cancer, or death from any cause. Secondary efficacy endpoints include overall survival (OS) rates for the entire population, as well as DFS and OS for specific subgroups such as ER+ and PR+ and ER+/PR- patients. Additional efficacy measures include event-free survival (EFS), distant metastasis-free survival (DMFS), and bone metastasis-free survival (BMFS). The trial will also assess the incidence of secondary cancers.

Biological efficacy assessments will involve the predictive value of mTOR activation markers on DFS, utilizing immunohistochemistry (IHC) analysis of the primary tumor for pS6K and p4EBP. Other translational analyses will be conducted to link cancer biology with clinical outcomes. Quality of life will be evaluated using the QLQ C30 instrument. The trial will also include a sociological study and assess EFS and DMFS in low-risk patients according to the EPClin score. The efficacy parameters will be collected and analyzed at specified timepoints throughout the trial duration, which is estimated to conclude by March 31, 2025.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Female ≥ 18 years of age
  • Histologically proven invasive unilateral or bilateral breast cancer (regardless of the morphological subtype)
  • Any T, M0
  • Patient with high risk of relapse
  • ER+ and HER2 negative : Hormone receptor positive is defined as any staining on the primary tumor, HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH non-amplified]
  • Primary tumor completely resected (deep margins and overlying skin involvement allowed if fully resected)
  • Patients who will begin an adjuvant hormone therapy or have received a maximum of 4 years of adjuvant hormone therapy. Hormone therapy could be either tamoxifen +/- LH-RH agonists, letrozole, anastrozole or exemestane
  • No clinically or radiologically detectable metastases at time of inclusion.
  • WHO Performance status (ECOG) of 0 or 1.
  • Adequate hematological function (neutrophil count  2x109/l, platelet count  100x 109/l)
  • Adequate hepatic function: AST and ALT ≤ 2.5 ULN, alkaline phosphatases ≤ 2.5 ULN, total bilirubin ≤ 2 ULN.
  • Adequate renal function: serum creatinine ≤ 1.5 ULN
  • Signed written informed consent.
cancel

Exclusion Criteria

  • Any local or regional recurrence or metastatic disease.
  • Any clinical or radiological suspicion of malignant or pre-malignant disease in the contralateral breast.
  • Patients with pN1mi as sole nodal involvement
  • Previous cancer (excepted basal cell carcinoma of the skin or in situ carcinoma of the cervix) in the preceding 5 years, including invasive contralateral breast cancer.
  • Patient already included in another ongoing therapeutic trial involving an unlicensed drug for which follow-up is required.
  • Patient who is pregnant or breast-feeding. Adequate birth control measures should be taken during the study treatment phase.
  • Patient with significantly impaired lung function (e.g. Chronic Obstructive Pulmonary Disease, respiratory insufficiency, Interstitial Lung Disease)
  • Positive serology for HIV infection or hepatitis C.
  • Chronic carrier of HBV (positive Antigen HbsAg positive in the blood)
  • Patient with chronic infection
  • Uncontrolled diabetes defined as glycated haemoglobin , HbA1c>7%
  • Uncontrolled hypercholesterolemia (cholesterol >300 mg/dl under adequate therapy).
  • Known hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients.
  • Patient with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study (e.g. patient who regularly require systemic steroids to control co-morbid disease).
  • Patient with any psychological, familial, social or geographical condition which could potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Belgium BelgiumNot Recruiting05 Jun 201326
France FranceNot Recruiting05 Jun 20131054

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Afinitor 5 mg tablets
TestTABLETSORAL1024PRD400622
PLACEBO
Placebo—ORAL024SUB21402

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Everolimus
35 trials

Also investigated for

Breast cancer 6Breast cancer metastatic 5Gastroenteropancreatic neuroendocrine tumour disease 4Hormone receptor positive HER2 negative breast cancer 4
vaccines
Placebo
90 trials

Also investigated for

Migraine 4Myocardial ischaemia 3Post-acute COVID-19 syndrome 3Chronic obstructive pulmonary disease 2